Drugs / HY-133
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06290557 | Jul 2024 → Jul 2025 overdue | staphylococcus aureus infection | University Hospital Tuebingen | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HY-133 | “As innovative product HY-133 a recombinant chimeric bacteriophage endolysin will be sprayed in both nostrils of healthy subjects once or five times in one day.” NCT06290557 ↗ |
| Modality | Protein / enzyme biologic | “A recombinant chimeric bacteriophage endolysin HY-133” NCT06290557 ↗ |
| Route | Intranasal | “will be sprayed in both nostrils” NCT06290557 ↗ |